Bryan Lewis

Patients can best advocate for themselves by asking questions and remembering they have the right to be active participants in their care.

There are many reliable resources available to patients with kidney cancer, as well as their families and caregivers.

Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.

Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.

A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.

Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.

An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.

Clinical nurse Kiran Virdee explains why a multidisciplinary treatment approach to clear cell renal cell carcinoma is beneficial.

An oncologist describes the necessity of discussing options with a patient when picking a treatment approach for clear cell renal cell carcinoma.

A review of clinical trial data on combination treatments for clear cell renal cell carcinoma.

Patients with clear cell renal cell carcinoma speak to their experiences with systemic treatments.

An overview of first-line treatment options for metastatic clear cell renal cell carcinoma.

Bryan Lewis, president of KidneyCAN, explains how his organization supports the renal cell carcinoma community and where patients can find curated educational resources.

Patient Meryl Uranga describes how she was diagnosed with metastatic clear cell renal cell carcinoma and the initial treatments she received.

Chung-Han Lee, M.D., provides background on clear cell renal cell carcinoma, including common symptoms and risk factors.